Project Grant R01AI197350
Award Date 8/25/26
Completion Date 7/31/31
Dollars Obligated $488K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The University of Central Florida Board Of Trustees $422,125 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize antimicrobial factors produced by nasal microbiota that inhibit Staphylococcus aureus colonization. The research addresses the public health threat posed by S. aureus nasal carriage, which serves as a reservoir for transmission and clinical...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $155,500 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate heterogeneity in Staphylococcus aureus virulence factor activity within neutrophils and its impact on bacterial survival and host-pathogen interactions. The research examines how an isogenic population of S. aureus generates bacteria with divergent outcomes upon interaction with...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $861,088 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a novel monoclonal antibody targeting enampt (extracellular nicotinamide phosphoribosyl transferase) to reduce antimicrobial resistance following hospital-acquired and ventilator-associated bacterial pneumonia. The research will employ preclinical models of pneumonia caused by...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $750,263 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacteriophage predation influences diarrheal disease severity and antimicrobial resistance emergence. The research uses cholera as a model system to validate findings in a new patient cohort and tests underlying theory across high-priority enteric pathogens including Shigella species and...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Rutgers, The State University $421,889 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cytosolic copper ion accumulation and proteome integrity in Staphylococcus aureus. The project addresses antimicrobial resistance in S. aureus and other ESKAPE pathogens by examining how copper ions toxify bacteria through protein misfolding and aggregation. The research characterizes...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement totaling $634,247 to the University of Maryland, Baltimore on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the role of penicillin-binding protein 4 (PBP4) in mediating antibiotic resistance and pathogenesis of Staphylococcus aureus. The research investigates how PBP4-mediated mutations enable high-level, broad-spectrum β-lactam...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $3,064,333 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how the host immune response influences methicillin-resistant Staphylococcus aureus susceptibility to antibiotics in skin and soft tissue infections. The research comprises three specific aims. Aim 1 examines how neutrophils enriched during the...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Florida Division of Sponsored Research $392,142 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanoparticle therapeutics for inflammatory bowel disease. The award funds development of an off-the-shelf therapeutic approach using polysaccharide A (PSA)–derived nanoparticles from commensal...